Mahal Jeetinder Singh 4
4 · Jasper Therapeutics, Inc. · Filed Mar 12, 2024
Insider Transaction Report
Form 4
Mahal Jeetinder Singh
DirectorCEO and President
Transactions
- Exercise/Conversion
Voting Common Stock
2024-03-12$7.10/sh+900$6,390→ 25,909 total - Sale
Voting Common Stock
2024-03-12$26.44/sh−900$23,792→ 25,009 total - Exercise/Conversion
Stock Option (right to buy)
2024-03-12+900→ 16,472 totalExercise: $7.10Exp: 2030-05-31→ Voting Common Stock (900 underlying)
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
- [F2]Effective on January 4, 2024, the Issuer conducted a reverse stock split of its voting common stock at a ratio of 1-for-10 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.79, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
- [F4]The exercise price of the option and number of shares subject to the option were adjusted as a result of the Reverse Split, and numbers reported herein reflect the exercise price and number of shares subject to the option after the Reverse Split.
- [F5]25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.